Sujan Lahiri

Cel-Sci's Undervaluation Is Market Irrationality At Its Best

Editors' Note: This article covers a stock trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.

Cel-Sci (NYSEMKT:CVM) is a lead investigational immunotherapy company which is developing a groundbreaking technology to treat head and neck cancer, as well as ways to enhance the body's immune system capability to fight bacterial, viral, and parasitic infections. It's a $65 million sized micro-cap listed on the AMEX. Just 2 weeks ago, a remarkable insider transaction took place:

(click to enlarge)

The CEO doubled his position by buying 300000 shares (!) directly in the open market - not an option transaction - at a price...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details